financetom
Business
financetom
/
Business
/
Update: TJX Shares Rise After Fiscal Q4 Beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: TJX Shares Rise After Fiscal Q4 Beat
Feb 26, 2025 8:13 AM

10:39 AM EST, 02/26/2025 (MT Newswires) -- (Updates with the latest stock movement in the headline and first paragraph and additional details in the eighth and ninth paragraphs.)

TJX (TJX) shares were up 1.9% in recent Wednesday trading after it reported fiscal Q4 results that topped analysts' expectations and announced its plan to raise the quarterly dividend.

The company reported fiscal Q4 earnings of $1.23 per diluted share, up from $1.22 a year earlier.

Analysts polled by FactSet expected $1.16.

Net sales for the quarter ended Feb. 1 were $16.35 billion, down from $16.41 billion a year earlier.

Analysts surveyed by FactSet expected $16.21 billion.

The company expects fiscal Q1 diluted EPS to be in the range of $0.87 to $0.89. Analysts polled by FactSet expect $0.98.

For fiscal 2026, the company expects diluted EPS of $4.34 to $4.43. Analysts surveyed by FactSet expect $4.56.

The company said it intends to raise its quarterly dividend by 13% to $0.425 per share, expected to be declared in March and payable in June.

Additionally, TJX said its board has authorized the company to buy back up to an additional $2.5 billion of its common shares during the current fiscal year ending on Jan. 31 next year. The new authorization represents about 1.8% of TJX's outstanding stock.

Price: 124.99, Change: +2.29, Percent Change: +1.87

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Geron Stock Is Falling Today
Why Geron Stock Is Falling Today
Mar 12, 2024
Geron Corporation ( GERN ) shares are trading lower Tuesday after FDA staff reviewers reportedly raised multiple safety concerns over Geron’s anemia drug, imetelstat.  The Details: According to the Reuters report, FDA staff said the “clinical meaningfulness” of the clinical data was unclear and pointed to a high rate of low red blood cell counts in the study. FDA staff...
SIGA Technologies Share Rise After Special Cash Dividend Announcement
SIGA Technologies Share Rise After Special Cash Dividend Announcement
Mar 12, 2024
02:32 PM EDT, 03/12/2024 (MT Newswires) -- SIGA Technologies ( SIGA ) shares were up more than 11% in recent Tuesday trading after the company's board declared a special cash dividend of $0.60 per share, up from the $0.45 per share dividend paid in June. The special dividend is payable on April 11 to shareholders of record on March 26,...
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients
Mar 12, 2024
02:46 PM EDT, 03/12/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) shares were down 9% in recent Tuesday trading after a new analysis of the company's sotagliflozin found similar effect on subjects enrolled in a phase 3 clinical trial and a subset of patients in the study. A post hoc analysis of the trial found that sotagliflozin led to...
Agilent Technologies Insider Sold Shares Worth $7,844,550, According to a Recent SEC Filing
Agilent Technologies Insider Sold Shares Worth $7,844,550, According to a Recent SEC Filing
Mar 12, 2024
02:43 PM EDT, 03/12/2024 (MT Newswires) -- Michael R. McMullen, Director, CEO and President, on March 08, 2024, sold 52,297 shares in Agilent Technologies ( A ) for $7,844,550. Following the Form 4 filing with the SEC, McMullen has control over a total of 253,909 shares of the company, with 253,909 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1090872/000112760224009663/xslF345X03/form4.xml Price: 147.50, Change:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved